Abstract
Cancer genome sequencing is useful for diagnosis and personalized treatment. Analysis of the sequencing data involves integration of computation, statistics and system biology methods. The amalgam of such methods which help study interaction of cancer cells with immune system, harnessing immune system for cancer therapy or its prevention through vaccines has led to the foundation of cancer immunomics. It is, therefore, a combinatorial science which merges diverse techniques from genomics and proteomics for diagnosis and drug design/treatment. There has been a gradual increase in establishment of cancer immune focused start-ups, research facilities and pharma giants working on state-of-the-art methods for improving diagnostics, treatment and prevention or minimizing side effects, applying immunomics. However, we are still far away from making precise, quick and reliable diagnostic and treatment predictions. We need decision support systems to facilitate diagnosis, tumor evaluation prediction and assessment of individual profile for making personalized therapy a reality. The future is centered not only on data management but wise decision aided by artificially intelligent algorithms. In this review, we provide an overall picture and focus on immune biomarkers and relevant softwares that aid in diagnostics and analysis of cancer.
Keywords: Immunomics, cancer informatics, immunoinformatics, diagnostics, biomarkers, personalized therapy.
Current Pharmaceutical Design
Title:Cancer Immunomics in the Age of Information: Role in Diagnostics and Beyond
Volume: 24 Issue: 32
Author(s): Zarrin Basharat, Azra Yasmin*Nosheen Masood
Affiliation:
- Microbiology & Biotechnology Research Lab, Department of Environmental Sciences, Fatima Jinnah Women University-46000, Rawalpindi,Pakistan
Keywords: Immunomics, cancer informatics, immunoinformatics, diagnostics, biomarkers, personalized therapy.
Abstract: Cancer genome sequencing is useful for diagnosis and personalized treatment. Analysis of the sequencing data involves integration of computation, statistics and system biology methods. The amalgam of such methods which help study interaction of cancer cells with immune system, harnessing immune system for cancer therapy or its prevention through vaccines has led to the foundation of cancer immunomics. It is, therefore, a combinatorial science which merges diverse techniques from genomics and proteomics for diagnosis and drug design/treatment. There has been a gradual increase in establishment of cancer immune focused start-ups, research facilities and pharma giants working on state-of-the-art methods for improving diagnostics, treatment and prevention or minimizing side effects, applying immunomics. However, we are still far away from making precise, quick and reliable diagnostic and treatment predictions. We need decision support systems to facilitate diagnosis, tumor evaluation prediction and assessment of individual profile for making personalized therapy a reality. The future is centered not only on data management but wise decision aided by artificially intelligent algorithms. In this review, we provide an overall picture and focus on immune biomarkers and relevant softwares that aid in diagnostics and analysis of cancer.
Export Options
About this article
Cite this article as:
Basharat Zarrin , Yasmin Azra *, Masood Nosheen, Cancer Immunomics in the Age of Information: Role in Diagnostics and Beyond, Current Pharmaceutical Design 2018; 24 (32) . https://dx.doi.org/10.2174/1381612824666181106091903
DOI https://dx.doi.org/10.2174/1381612824666181106091903 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Silimarin and Cancer
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs: An Apparent Switch for High-Altitude Pulmonary Edema
MicroRNA PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science Synthesis and Biological Evaluation of Novel Thiazol-2yl-amine Derivatives as Potential Anticancer Agents
Letters in Organic Chemistry Treatment and Response to Statins: Gender-related Differences
Current Medicinal Chemistry Quadruplex DNA: A Promising Drug Target for the Medicinal Inorganic Chemist
Current Topics in Medicinal Chemistry Pro-Oxidative Action of Polyphenols as Action Mechanism for their Pro-Apoptotic Activity
Anti-Cancer Agents in Medicinal Chemistry Discovery of a Highly Potent and Novel Gambogic Acid Derivative as an Anticancer Drug Candidate
Anti-Cancer Agents in Medicinal Chemistry Development of Microfluidic-based Analytical Methodology for Studying the Effects of Chemotherapy Agents on Cancer Tissue
Current Analytical Chemistry Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry An Optimised Radiolabel Procedure to Prepare 99mTc-Colloidal Rhenium Sulphide to Improve Radiochemical Purity
Current Radiopharmaceuticals Anti-tumor Efficacy of a Recombinant Human Arginase in Human Hepatocellular Carcinoma
Current Cancer Drug Targets Antimicrobial Chitosan based Formulations with Impact on Different Biomedical Applications
Current Pharmaceutical Biotechnology Epigenetic and miRNAs Dysregulation in Prostate Cancer: The role of Nutraceuticals
Anti-Cancer Agents in Medicinal Chemistry Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development
Current Bioactive Compounds Preparation, Photoluminescence and Antimicrobial Activity of Loracarbef and its Various Complexes
Current Analytical Chemistry Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy
Current Stem Cell Research & Therapy